Form 4: First Wave BioPharma CEO Sells Shares to Cover Tax Obligations

James Sapirstein, CEO of First Wave BioPharma, sold shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Summary

• On April 1, 2024, James Sapirstein, the Chairman and CEO of First Wave BioPharma, Inc. (FWBI), sold 174 shares of common stock at a price of $4.2294 per share.
• The sale was executed to cover tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The transaction was mandated by First Wave BioPharma's policy requiring tax obligations to be met through a 'sell to cover' transaction.
• Following the transaction, Sapirstein directly owns 37,105 shares, including unvested RSUs.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale for tax purposes. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CEO, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Stakeholder Impact

• The share sale has a minimal impact on shareholders as it is a small transaction related to tax obligations.

Key Dates

Keywords

Form 4, First Wave BioPharma, FWBI, James Sapirstein, CEO, Share Sale, Restricted Stock Units, RSUs, Tax Withholding, Sell to Cover